Pharsight

Altabax patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7875630 ALMIRALL Process salts compositions and use
Feb, 2027

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE43390 ALMIRALL Pleuromutilin derivatives as antimicrobials
Apr, 2021

(3 years ago)

USRE39128 ALMIRALL Pleuromutilin derivatives as antimicrobials
Apr, 2021

(3 years ago)

US8207191 ALMIRALL Process, salts, composition and use
Aug, 2024

(3 months from now)

Altabax is owned by Almirall.

Altabax contains Retapamulin.

Altabax has a total of 4 drug patents out of which 2 drug patents have expired.

Expired drug patents of Altabax are:

  • USRE43390
  • USRE39128

Altabax was authorised for market use on 12 April, 2007.

Altabax is available in ointment;topical dosage forms.

Altabax can be used as treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes.

Drug patent challenges can be filed against Altabax from 13 April, 2011.

The generics of Altabax are possible to be released after 14 February, 2027.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 12, 2012

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using RETAPAMULIN ingredient

NCE-1 date: 13 April, 2011

Market Authorisation Date: 12 April, 2007

Treatment: Treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes

Dosage: OINTMENT;TOPICAL

More Information on Dosage

ALTABAX family patents

Family Patents